Humoral response to <scp>mRNA</scp>‐based <scp>COVID</scp>‐19 vaccine in patients with myeloid malignancies
Akio Mori, Masahiro Onozawa, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Makoto Saito, Haruna Muraki, Masanobu Morioka, Takanori Teshima, Takeshi Kondo
Abstract
Data on the response to the COVID-19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti-spike SARS-CoV-2 antibody titres were measured 3 months after the second mRNA-based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID-19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.